Nguyen T D, Malissard L, Théobald S, Eschwège F, Panis X, Bachaud J M, Rambert P, Chaplain G, Quint R
Institut Jean-Godinot, Reims, France.
Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1013-8. doi: 10.1016/s0360-3016(96)00355-0.
Induction chemotherapy has been proposed in the case of advanced laryngeal cancer in order to preserve laryngeal function in those patients who are complete responders. To clarify the treatment policies, a retrospective multicentric analysis of 116 patients with advanced carcinoma of the larynx treated by radical surgery and postoperative radiotherapy was carried out in order to evaluate prognostic factors for local control and survival.
Between 1980 and 1985, 116 patients with Stage III squamous cell carcinoma of the larynx underwent radical surgery and postoperative radiotherapy with a curative intent. Treatments were very homogenous, and doses delivered were in the range of 50-65 Gy according to nodal involvement and surgical margins status.
The local recurrence rate and the local disease-free survival rate at 5 years were 22.5% and 76.3%, respectively. Actuarial survival at 5 years was 68.3% with 44 patients still alive with no evidence of disease (NED) with more than 5 years follow-up. For both overall survival and relapse-free survival, cervical node involvement with capsular rupture was found to be the only significant adverse pronostic factor in univariate and multivariate analysis. No other parameter was predictive either for local recurrence or for survival.
Local prognosis and survival depend largely on nodal involvement and capsular rupture while increasing doses of radiation strategy is likely to reduce the risk of local and nodal recurrence. Preservation of functional larynx is certainly an important goal to achieve when treating advanced carcinoma of the larynx, provided that local failure rate and survival be similar. In the unique randomized study previously published in the literature comparing radical surgery and postoperative radiotherapy to induction chemotherapy and radiotherapy, the local-regional failure rate was drastically increased in the chemotherapy arm. Other results from well-designed controlled studies are awaited before recommending systematic induction chemotherapy and larynx preservation in complete responders. On the other hand, testing synchronous or alternated chemotherapy vs. induction chemotherapy may address the pending questions about the optimal treatment of advanced laryngeal carcinoma.
对于晚期喉癌患者,已提出采用诱导化疗,以便在那些完全缓解的患者中保留喉功能。为明确治疗策略,对116例接受根治性手术及术后放疗的晚期喉癌患者进行了回顾性多中心分析,以评估局部控制和生存的预后因素。
1980年至1985年间,116例Ⅲ期喉鳞状细胞癌患者接受了根治性手术及术后放疗,目的是治愈。治疗方法非常一致,根据淋巴结受累情况和手术切缘状态,给予的剂量在50 - 65 Gy范围内。
5年局部复发率和局部无病生存率分别为22.5%和76.3%。5年精算生存率为68.3%,44例患者在超过5年的随访后仍存活且无疾病证据(NED)。对于总生存和无复发生存,在单因素和多因素分析中,发现伴有包膜破裂的颈部淋巴结受累是唯一显著的不良预后因素。没有其他参数可预测局部复发或生存情况。
局部预后和生存很大程度上取决于淋巴结受累和包膜破裂,而增加放疗剂量策略可能会降低局部和淋巴结复发的风险。在治疗晚期喉癌时,保留功能性喉肯定是一个重要目标,前提是局部失败率和生存率相似。在先前文献中发表的唯一一项比较根治性手术及术后放疗与诱导化疗及放疗的随机研究中,化疗组的局部区域失败率大幅增加。在推荐对完全缓解者进行系统性诱导化疗和保留喉之前,还需等待精心设计的对照研究的其他结果。另一方面,测试同步或交替化疗与诱导化疗可能会解决关于晚期喉癌最佳治疗的悬而未决的问题。